Navigation Links
Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Date:5/12/2011

SAN FRANCISCO, May 12, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that key data from its Phase 2 randomized clinical study in advanced liver cancer patients, along with data from other JX-594 clinical trials, will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 18-21, 2011, in Seattle, Washington.  These data, evaluating multi-dose administration of JX-594 in U.S., Korean and Canadian patients with advanced liver cancer, were selected for an oral presentation at the ASGCT Presidential Symposium. Additionally, these data have been chosen for inclusion in ASGCT's Media Event to be held during the annual meeting.

The presentation details are as follows:

Abstract Title: "Demonstration of Safety and Antitumoral Activity of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, Following Intravenous Infusion and/or Intratumoral Injections in Patients with Refractory Metastatic Cancers" (Abstract #50)

Presenter: David H. Kirn, M.D., president and chief executive officer of Jennerex

Session: Presidential Symposium, May 19, 2011, 9:05 a.m. PDT

About JX-594

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
2. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
3. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
4. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
5. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Closes $5 Million First Tranche of Series C Financing
8. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
9. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
10. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
11. Micell Technologies Reports Preclinical Data for MiStentâ„¢ Drug-Eluting Coronary Stent to be Presented at EuroPCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
(Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
(Date:8/25/2015)... 25, 2015   WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... Hong Kong Exchange Stock Code: 0950), a research-based biopharmaceutical ... with 20 years of operations in China ... signed an agreement whereby WuXi,s Laboratory Testing Division (LTD) ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... Board: KDUS) announced today financial results for the first,quarter ended ... 2008 were $100,000, compared to,$100,000 for the same period in ... compared to net loss of $558,469 for the same period ... a decrease in general,and administrative expenses of $47,207 and the ...
... Pharmaceutical Services, Inc.,(JOM), a service coordinator that provides ... Ortho Biotech, L.P., was notified May 6,2008, that ... PROCRIT(R) (epoetin alfa) and REMICADE(R) (infliximab) was,stolen while ... in,Kentucky to a specialty distributor. This incident has ...
... MedImmune today announced,that researchers will present eight ... Annual Meeting of the American Thoracic Society, ... Canada. Presentations are designed to showcase,MedImmune,s biologics ... innovative solutions that may one,day help patients ...
Cached Biology Technology:Cadus Reports First Quarter 2008 Results 2Cadus Reports First Quarter 2008 Results 3Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product 2Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product 3Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product 4Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society 2
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
(Date:8/10/2015)... and TELTOW, Germany , ... Instruments (SMI), a world leader in Eye Tracking ... completion of its OEM Eye Tracking Platform for integration ... Tracking Platform contains reference designs for seamless integration of ... systems, virtual reality HMDs and augmented reality smart glasses. ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... defeat is influenced by his or her stance on ... of the most recent presidential and congressional elections. ... candidates, statements on climate change translated into real votes," ... science at Stanford, who led two new studies ...
... Administration (FDA) has awarded the Georgia Institute of ... Saint Joseph,s Translational Research Institute (SJTRI) a two-year, ... medical devices focused on the special needs of ... Pediatric Device Consortium, which will provide assistance with ...
... October 2011, Singapore A new biotech company has ... (NUS), to provide research tools, targeting the international malaria ... founded by two NUS faculty members: Dr Martin Lear ... Tan from the NUS Department of Microbiology. The company ...
Cached Biology News:Stanford researchers examine impact of 'green politics' on recent national elections 2Stanford researchers examine impact of 'green politics' on recent national elections 3FDA grant launches Atlanta Pediatric Device Consortium 2FDA grant launches Atlanta Pediatric Device Consortium 3FDA grant launches Atlanta Pediatric Device Consortium 4Launch of BioLynx provides a boost for the international malaria research community 2
... Satellite Thermal Cycler (MBS) is ... for medium to high throughput ... the latest in satellite block ... PC control, resulting in a ...
... 2 Block MBS Start up kit. Includes ... and choice of 2 MultiBlock satellite ... 30 blocks. User friendly software. ... Adjustable height heated lid. Outstanding uniformity. ...
... of VARIOMAG Magnetic Stirrers operate without any ... mechanical bearings, making VARIOMAG Magnetic Stirrers 100% ... inductive drive can be hermetically sealed, making ... This is why VARIOMAG Magnetic Stirrers are ...
... Enzymatic method stops PCR carry-over ... ,Designed to degrade PCR products from ... nucleic acid templates, which improves amplification ... core reagents and GeneAmp instrument systems ...
Biology Products: